This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeoStem Announces Further Expansion Of Intellectual Property Coverage

NEW YORK, Jan. 22, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) today announced the expansion of intellectual property protection around its lead product candidate, AMR-001, with the grant of U.S. patent number 8,343,485 entitled "Compositions and methods of Vascular Injury Repair." This is the third U.S. granted patent for AMR-001, protecting further expansion of its CD34+ chemotactic stem cell product composition claim as well as method of sourcing and administration of cells claims.

Dr. Andrew L. Pecora, Chief Medical Officer of NeoStem, commented, "NeoStem's intellectual property portfolio around its phase 2 stem cell compound continues to expand in critical ways. With the grants of its last three U.S. patents, AMR-001 now enjoys greater protection in terms of its CD34 cell content and the indications for its use, which include treating any vascular injury caused by vascular insufficiency, covering CD34 stem cells sourced from bone marrow or peripheral blood and administered parenterally into an artery, vein or muscle."

"This successful expansion of NeoStem's intellectual property improves our ability to protect our most mature clinical asset," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "We believe the IP around AMR-001, our stem cell therapy, is strong and broad and we continue to pursue incremental protection with no fewer than 30 additional patents pending around the world."

For more information on the clinical trial please visit or view the NeoStem corporate presentation at To read the complete patent, please visit .

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs